October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 07, 2025

EASO Issues Obesity Pharmacotherapy Guidance

EASO framework guides obesity drug selection by weight loss effect and complication focus.

Conexiant

September 29, 2025

Clinicians: Ultraprocessed Food Limits Coming to Cafeterias?

States consider bipartisan bans on ultraprocessed foods in schools over obesity and child health.

KFF Health News

September 24, 2025

Surgery Versus GLP-1: Long-Term Diabetes Outcomes

Metabolic surgery associated with lower mortality and retinopathy risk versus glucagon-like peptide-1 therapy in diabetes and obesity.

Conexiant

September 23, 2025

Global Consensus Streamlines MASLD/MASH Care

"We have developed consensus recommendations for busy clinicians."

Conexiant

September 05, 2025

Ancillary Features Don’t Improve LI-RADS Accuracy

The study raises questions about whether ancillary features still warrant inclusion in liver imaging workflows.

Conexiant

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant